English (international)
Eesti
Български
Deutsch
Français
Español (Latinoamérica)
Polski
Magyar
Română
ACADIA Pharmaceuticals Inc
Closed
Sector Healthcare
19.16 3.23
Overview
Share price change
24h
Min
18.53
Max
19.2
Income | -29M 17M |
|---|---|
Sales | -25M 206M |
EPS | 0.1 |
Profit margin | 8.044 |
Employees | 597 |
EBITDA | -16M 21M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +50.3 upside |
Next Earnings | 6 sie 2024 |
|---|
Market Cap | 354M 3B |
|---|---|
Previous open | 15.93 |
Previous close | 19.16 |
News Sentiment
By Acuity
100%
0%
345 / 369 Ranking in Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
ACADIA Pharmaceuticals Inc Chart
Related News
Peer Comparison
Price change
ACADIA Pharmaceuticals Inc Forecast
Price Target
By TipRanks
50.3% upside
12 Months Forecast
Average 27.88 USD 50.3%
High 39 USD
Low 17 USD
Based on 16 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
EBITDA
Operating profit
$
About ACADIA Pharmaceuticals Inc
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).
